What's Happening?
Verastem Oncology has commenced the TARGET-D 202 Phase 2 trial to evaluate VS-7375, an investigational oral inhibitor targeting KRAS G12D mutations in advanced non-small cell lung cancer (NSCLC). This trial marks a significant step as it is the second
registration-directed Phase 2 clinical trial for VS-7375, following a similar study for metastatic pancreatic cancer. The trial will assess the efficacy and safety of VS-7375 in patients whose disease has progressed after prior treatments, including platinum-based chemotherapy and anti-PD-(L)1 therapy. The study also includes a cohort for patients with asymptomatic untreated brain metastases. KRAS G12D mutations are prevalent in various cancers, including pancreatic, colorectal, and lung cancers, but no FDA-approved therapies specifically target this mutation.
Why It's Important?
The initiation of this trial is crucial as it addresses a significant unmet need in cancer treatment. KRAS G12D mutations are associated with poor outcomes and resistance to existing therapies, particularly in NSCLC. By targeting both the active and inactive states of the KRAS G12D mutation, VS-7375 has the potential to offer a more comprehensive treatment option. This development could lead to improved progression-free survival rates for patients, who currently face limited options. The success of this trial could pave the way for new, targeted therapies that improve survival rates and quality of life for patients with KRAS G12D-mutated cancers.
What's Next?
Verastem plans to continue expanding its clinical program for VS-7375, with additional trials targeting other KRAS G12D-driven cancers. The company aims to provide updates on the trial's progress and potential regulatory strategies. If successful, these trials could lead to the approval of VS-7375, offering a new treatment option for patients with limited alternatives. The broader clinical development of VS-7375 could also facilitate its use in combination therapies, potentially enhancing its efficacy and reducing side effects compared to non-specific inhibitors.
